

FOOD AND DRUG ADMINISTRATION

Center for Tobacco Products (CTP)

Tobacco Products Scientific Advisory Committee (TPSAC)

9200 Corporate Boulevard, Rockville, MD 20850

January 18-20, 2012

January 18, 2012 – afternoon session

The committee will continue the discussions of issues related to the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children, as part of the TPSAC's required report to the Secretary of Health and Human Services. Discussion will include such topics as the composition and characteristics of dissolvable tobacco products, product use, potential health effects, and marketing.

2:00	Call to Order	Jonathan Samet, M.D., M.S. Chair, TPSAC
2:05	Conflict of Interest Statement	Caryn Cohen, M.S. Designated Federal Official, FDA/CTP
2:10	Introduction of Committee Members	Jonathan Samet, M.D., M.S. Chair, TPSAC
2:15	Opening Remarks	Sarah E. Evans, Ph.D. Social Scientist Office of Science, FDA/CTP

Presentations:

2:30	The Swedish Tobacco Harm Reduction Experience	Lars-Erik Rutqvist, M.D., Ph.D. Senior Vice President for Scientific Affairs Swedish Match, Smokefree Division
2:50	Smokeless Tobacco, Cigarettes, and Dual Product Use: Implications for Dissolvable Product Marketing	Scott L. Tomar, D.M.D., M.P.H., Dr.P.H. Professor, University of Florida College of Dentistry
3:10	Committee discussion of Question 1	

January 19, 2012

8:00	Call to Order	Jonathan Samet, M.D., M.S. Chair, TPSAC
8:05	Conflict of Interest Statement	Caryn Cohen, M.S. Designated Federal Official, FDA/CTP
8:10	Introduction of Committee Members	Jonathan Samet, M.D., M.S. Chair, TPSAC
8:15	Opening Remarks	Sarah E. Evans, Ph.D. Social Scientist Office of Science, FDA/CTP
	<u>Presentations:</u>	
8:30	Health Effects of Dissolvable Tobacco Products	Ii-Lun Chen, M.D. Medical Officer Office of Science, FDA/CTP
8:50	Health Effect of Long-term Use of Therapeutic NRT	Priscilla Callahan-Lyon, M.D. Division of Nonprescription Clinical Evaluation, FDA/CDER
9:10	Committee Discussion	
9:30	Break	
9:45	Toxic and Carcinogenic Constituents In Dissolvable Tobacco Products	Irina Stepanov, Ph.D. Chemist, University of Minnesota
10:05	Quantitative and Qualitative Analysis of Dissolvable Tobacco Products	Clifford Watson, Ph.D. Lead Research Chemist, CDC
10:25	Topography of Use; Nicotine Absorption	Sarah E. Evans, Ph.D. Social Scientist Office of Science, FDA/CTP
10:45	Indiana's Experience: Marketing of Dissolvable Tobacco Products	Miranda Spitznagle, M.P.H. Director of Program Evaluation Indiana Tobacco Prevention and Cessation Commission

11:05	Committee Discussion	
11:30	Lunch	
12:30	Data on Accidental Ingestions: With Focus on Pediatric Ingestions	Ii-Lun Chen, M.D. Medical Officer Office of Science, FDA/CTP
12:50	CPSC and the Poison Prevention Packaging Act	John W. Boja, Ph.D. Consumer Product Safety Commission
2:10	Committee Discussion	
2:30	Review of Peer-Reviewed Literature Regarding Dissolvable Tobacco Products	Linda Brown, M.P.H., Dr.P.H. RTI
2:50	Committee Discussion	
3:00	Break	
3:15	Open Public Hearing	
4:15	Review of Industry Documents Regarding Dissolvable Tobacco Products	RTI International
4:20	Overview	Jeanette Renaud, Ph.D.
	Behavioral Effects	Jeanette Renaud, Ph.D.
4:40	Health Effects of Dissolvable Tobacco Products	Linda Brown, M.P.H., Dr.P.H.
4:50	Marketing Research and Marketing Practices	Brian Southwell, Ph.D.
4:55	Toxicological & Physiological Effects	Brian Thomas, Ph.D.
5:00	Adjourn	

January 20, 2012

8:00	Call to Order	Jonathan Samet, M.D., M.S. Chair, TPSAC
8:05	Conflict of Interest Statement	Caryn Cohen, M.S. Designated Federal Official, FDA/CTP
8:10	Introduction of Committee Members	Jonathan Samet, M.D., M.S. Chair, TPSAC
8:15	Opening Remarks	Sarah E. Evans, Ph.D. Social Scientist, FDA/CTP
8:30	College Students' Awareness and Perceptions of Dissolvable Tobacco Products	Mark Wolfson, Ph.D. Professor, Social Sciences and Health Policy Wake Forest School of Medicine
9:00	Survey Findings from Virginia	Virginia Foundation for Healthy Youth: -Danny Saggese -Jeff Jordon -Judy Hou
9:30	Committee Discussion	
10:00	Break	
10:15	Committee Discussion:	
		<ul style="list-style-type: none">▪ Proposed Conceptual Framework▪ Questions to the Committee
12:00	Lunch	
1:00	Committee Discussion – (continued)	
4:00	Adjourn	